Osamu Narumoto, Yukiko Matsuo, Masahiro Sakaguchi, Shunsuke Shoji, Naohide Yamashita, David Schubert, Kazuho Abe, Kazuhide Horiguchi, Takahide Nagase, Naomi Yamashita
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 93(1) 18-25, Aug, 2012 Peer-reviewed
To advance the control of airway epithelial cell function and asthma, we investigated the effects of a new curcumin derivative, CNB001, which possesses improved pharmacological properties. Normal human bronchial epithelial (NHBE) cells were stimulated with synthetic double-stranded RNA, Poly(I:C). CNB001 significantly suppressed IL-6, TNF-alpha, and GM-CSF production by NHBE cells, and did so more effectively than did curcumin or dexamethasone (DEX). CNB001 significantly inhibited the decrease of E-cadherin mRNA expression and increase of vimentin mRNA expression observed in NHBE cells induced by a combination of TGF-beta 1 and TNF-alpha, which are markers of airway remodeling. In NHBE cells stimulated by TGF-beta 1, CNB001 significantly downregulated the level of active serine peptidase inhibitor clade E member (SERPINE) 1, which is also reported to be related to airway remodeling. Whereas DEX alone significantly increased the active SERPINE1 level, the combination of DEX and CNB001 significantly suppressed active SERPINE1. In addition, CNB001 significantly suppressed neutrophil infiltration, IL-6, TNF-alpha, IL-13 and active SERPINE1 production in bronchoalveolar lavage fluid of the murine asthma model, which was not observed in the case of DEX. In conclusion, the curcumin derivative, CNB001, is a promising candidate to treat asthma associated with neutrophilic airway inflammation and remodeling. (C) 2012 Elsevier Inc. All rights reserved.